Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:administered_by |
oral route
|
| gptkbp:administration_age |
administered to infants
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
conducted for safety and efficacy
|
| gptkbp:community_health |
critical in polio eradication efforts
|
| gptkbp:community_impact |
significantly reduced polio cases
|
| gptkbp:contraindication |
severe allergic reaction
|
| gptkbp:defense |
recommended for use in polio-endemic areas
|
| gptkbp:developed_by |
gptkb:Albert_Bruce_Sabin
|
| gptkbp:diseases |
gptkb:poliomyelitis
|
| gptkbp:distribution |
global vaccination campaigns
|
| gptkbp:dosage_form |
recommended in some cases
|
| gptkbp:dose_schedule |
multiple doses
|
| gptkbp:first_introduced |
gptkb:1961
|
| gptkbp:formulation |
drops
|
| https://www.w3.org/2000/01/rdf-schema#label |
oral poliovirus vaccine
|
| gptkbp:is_effective_against |
high
|
| gptkbp:is_vulnerable_to |
developed in the 1950s
requires refrigeration live attenuated ongoing research for improvements considered safe for use easy to administer monitored for adverse events new formulations being researched WHO and CDC guidelines awareness campaigns necessary for uptake distributed through health systems effective in outbreak control engagement with local communities essential generally low cost has led to polio-free regions high efficacy in field studies important for global health security increased access in developing countries induces strong immune response part of global polio eradication initiative requires public education campaigns surveillance for polio cases continues vaccine hesitancy in some populations collaboration with NGOs and governments |
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:replaced_by |
inactivated poliovirus vaccine in some countries
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
rare cases of vaccine-derived poliovirus
mild gastrointestinal symptoms |
| gptkbp:success_rate |
over 90% in preventing polio
|
| gptkbp:target_audience |
children under 5 years old
|
| gptkbp:type |
live attenuated vaccine
|
| gptkbp:used_for |
preventing poliomyelitis
|
| gptkbp:vaccine_ethics |
ethical considerations in vaccine distribution
|
| gptkbp:vaccine_funding |
funded by international organizations
|
| gptkbp:vaccine_impact_assessment |
assessed for impact on public health
|
| gptkbp:vaccine_legislation |
supported by public health legislation
|
| gptkbp:vaccine_outreach |
community outreach programs
|
| gptkbp:vaccine_partnership |
partnerships with private sector
|
| gptkbp:vaccine_policy |
influences vaccination policy decisions
|
| gptkbp:vaccine_regulation |
regulated by health authorities
|
| gptkbp:vaccine_success |
considered a public health success story
|
| gptkbp:bfsParent |
gptkb:inactivated_poliovirus
|
| gptkbp:bfsLayer |
7
|